S A Shakir1, L V Wilton, A Boshier, D Layton, E Heeley. Show Affiliations » 1. Drug Safety Research Unit, Bursledon Hall, Southampton SO31 1AA. saad.shakir@dsru.org
Abstract
Entities: Chemical
Mesh: See more » 3',5'-Cyclic-GMP Phosphodiesterases/antagonists & inhibitorsAdolescentAdultAgedAged, 80 and overCardiovascular Diseases/chemically inducedCardiovascular Diseases/mortalityCause of DeathDrug PrescriptionsEngland/epidemiologyErectile Dysfunction/drug therapyFollow-Up StudiesHumansMaleMiddle AgedPhosphodiesterase Inhibitors/adverse effectsPhosphodiesterase Inhibitors/therapeutic usePiperazines/adverse effectsPiperazines/therapeutic usePurinesSildenafil CitrateSulfonesSurvival Rate
Substances: See more » Phosphodiesterase InhibitorsPiperazinesPurinesSulfonesSildenafil Citrate3',5'-Cyclic-GMP Phosphodiesterases
Year: 2001 PMID: 11250850 PMCID: PMC26545 DOI: 10.1136/bmj.322.7287.651
Source DB: PubMed Journal: BMJ ISSN: 0959-8138